Soluble Urokinase-Type Plasminogen Activator Receptor Improves Risk Prediction in Patients With Chronic Heart Failure
- 1 April 2017
- journal article
- Published by Elsevier in JACC: Heart Failure
- Vol. 5 (4) , 268-277
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- Soluble Urokinase Receptor and Chronic Kidney DiseaseNew England Journal of Medicine, 2015
- Biomarkers of renal injury and function: diagnostic, prognostic and therapeutic implications in heart failureEuropean Heart Journal, 2015
- Innate Immunity and the Failing HeartCirculation Research, 2015
- A reassessment of soluble urokinase-type plasminogen activator receptor in glomerular diseaseKidney International, 2015
- Natriuretic peptide-guided heart failure managementEuropean Heart Journal, 2013
- Usefulness of suPAR as a biological marker in patients with systemic inflammation or infection: a systematic reviewIntensive Care Medicine, 2012
- Circulating soluble urokinase plasminogen activator receptor predicts cancer, cardiovascular disease, diabetes and mortality in the general populationJournal of Internal Medicine, 2010
- suPAR: The Molecular Crystal BallDisease Markers, 2009
- IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling systemJournal of Clinical Investigation, 2007
- Trends in Heart Failure Incidence and Survival in a Community-Based PopulationJAMA, 2004